H3 receptor antagonist
H3 receptor antagonist is a class of drugs that selectively block the action of histamine at the H3 receptor, a subtype of histamine receptor. These drugs have potential therapeutic applications in the treatment of various central nervous system disorders.
History[edit | edit source]
The H3 receptor was first identified in the early 1980s, and the development of H3 receptor antagonists began in the late 1980s. The first H3 receptor antagonist to be discovered was Thioperamide, which was found to have potent and selective H3 receptor antagonist activity.
Mechanism of action[edit | edit source]
H3 receptor antagonists work by blocking the action of histamine at the H3 receptor. This receptor is found predominantly in the brain and is involved in a variety of functions, including the regulation of sleep and wakefulness, cognition, and appetite. By blocking the action of histamine at the H3 receptor, these drugs can enhance neurotransmitter release and improve cognitive function.
Therapeutic applications[edit | edit source]
H3 receptor antagonists have potential therapeutic applications in a variety of central nervous system disorders. These include narcolepsy, Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). They may also have potential in the treatment of obesity due to their ability to suppress appetite.
Examples[edit | edit source]
Examples of H3 receptor antagonists include Thioperamide, Ciproxifan, and Pitolisant. Pitolisant is the first H3 receptor antagonist to be approved for the treatment of narcolepsy in the European Union and the United States.
Safety and side effects[edit | edit source]
Like all drugs, H3 receptor antagonists can have side effects. These can include insomnia, nausea, and headache. However, these side effects are generally mild and temporary.
Future research[edit | edit source]
Research into H3 receptor antagonists is ongoing, with many potential new drugs in the pipeline. This research is focused on improving the efficacy and safety of these drugs, as well as exploring their potential in the treatment of other disorders.
This article is a neuroscience stub. You can help WikiMD by expanding it!
H3 receptor antagonist gallery[edit | edit source]
Thioperamide structure
Pitolisant structure
H3 receptor antagonists SAR
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
